Asset Details
Do you wish to reserve the book?
Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China
Do you wish to request the book?
Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China
2021
Overview
Antimicrobial resistance (AMR) poses a serious threat to global public health. However, vaccinations have been largely undervalued as a method to hinder AMR progression. This study examined the AMR impact of increasing pneumococcal conjugate vaccine (PCV) coverage in China. China has one of the world’s highest rates of antibiotic use and low PCV coverage. We developed an agent-based DREAMR (Dynamic Representation of the Economics of AMR) model to examine the health and economic benefits of slowing AMR against commonly used antibiotics. We simulated PCV coverage, pneumococcal infections, antibiotic use, and AMR accumulation. Four antibiotics to treat pneumococcal diseases (penicillin, amoxicillin, third-generation cephalosporins, and meropenem) were modeled with antibiotic utilization, pharmacokinetics, and pharmacodynamics factored into predicting AMR accumulation. Three PCV coverage scenarios were simulated over 5 y: 1) status quo with no change in coverage, 2) scaled coverage increase to 99% in 5 y, and 3) accelerated coverage increase to 85% over 2 y followed by 3 y to reach 99% coverage. Compared to the status quo, we found that AMR against penicillin, amoxicillin, and third-generation cephalosporins was significantly reduced by 6.6%, 10.9%, and 9.8% in the scaled scenario and by 10.5%, 17.0%, and 15.4% in the accelerated scenario. Cumulative costs due to AMR, including direct and indirect costs to patients and caretakers, were reduced by $371 million in the scaled and $586 million in the accelerated scenarios compared to the status quo. AMR-reducing benefits of vaccines are essential to quantify in order to drive appropriate investment.
Publisher
National Academy of Sciences
Subject
Anti-Bacterial Agents - pharmacology
/ Anti-Bacterial Agents - therapeutic use
/ Female
/ Health Care Costs - statistics & numerical data
/ Humans
/ Infant
/ Male
/ Mass Vaccination - economics
/ Mass Vaccination - statistics & numerical data
/ Pneumococcal Infections - economics
/ Pneumococcal Infections - microbiology
/ Pneumococcal Infections - mortality
/ Pneumococcal Infections - prevention & control
/ Pneumococcal Vaccines - administration & dosage
/ Pneumococcal Vaccines - economics
/ Vaccination Coverage - economics
/ Vaccination Coverage - statistics & numerical data
